Jump to content
RemedySpot.com

Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine

Rate this topic


Recommended Posts

Posted

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01412.x/abstract

Clinical features and risk factors of creatine kinase elevations and myopathy

associated with telbivudine

X. J. Zou, X. Q. Jiang, D. Y. TianArticle first published online: 23 DEC 2010

DOI: 10.1111/j.1365-2893.2010.01412.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Articles online in advance of print)

Summary.  With the extensive use of telbivudine, more and more studies

reported its association with creatine kinase (CK) elevations and myopathy.

However, clinical features of these adverse effects were poorly understood. The

aim of the present study was to investigate the clinical features and risk

factors of CK elevations and myopathy associated with telbivudine. The serum CK

levels of 200 patients who were treated with telbivudine for chronic hepatitis B

(CHB) between January 2007 and July 2010 were monitored and analysed along with

clinical manifestations. The 3-year cumulative incidence of CK elevations and

myopathy was 84.3% and 5%, respectively. CK elevations occurred more frequently

in men than in women, and patients aged ≤45 years and with negative HBeAg had

higher incidence of CK elevations. There was no difference in CK elevations

among patients with different HBV DNA levels. Male, younger age and HBeAg

negativity were independent predictors of CK elevations by multivariate

regression analysis. There was no association between the occurrence of myopathy

and variables including age, sex, HBeAg and HBV DNA. No risk factors of myopathy

were identified. CK elevations usually occurred 21 months after starting

treatment, and most patients resolved spontaneously without interruption of

telbivudine therapy except three patients who had to switch to other agents. In

conclusion, CK elevations are common adverse reactions associated with

telbivudine therapy, while myopathy is rare. Male, younger age and HBeAg

negativity might be risk factors of CK elevations.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...